AnPac Bio-Medical Science

Anpac Bio-Medical Science Company, Ltd. specializes in early cancer and disease screening using its proprietary Cancer Differentiation Analysis (CDA) liquid biopsy technology. This non-invasive method assesses multiple microscopic parameters in whole blood samples, often identifying cancer pre-Stage One. With over 80,000 cases validating its efficacy, Anpac's CDA technology demonstrates a sensitivity and specificity rate of 70%-95% for over 26 different types of cancer. The company serves healthcare providers and operates in the biomedical and diagnostic markets. Anpac Bio generates revenue through the sale of its screening and diagnostic services, offering a cost-effective alternative to traditional testing methods. The company promotes a culture of creativity, teamwork, and social responsibility.

Keywords: cancer detection, liquid biopsy, non-invasive, blood samples, diagnostics, healthcare, biomedical, CDA technology, sensitivity, specificity.